Subcutaneous Administration of Bortezomib in Combination with Thalidomide and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma Patients

Objective. To investigate the efficacy and safety of the treatment of the newly diagnosed multiple myeloma (MM) patients with the therapy of subcutaneous (subQ) administration of bortezomib and dexamethasone plus thalidomide (VTD) regimen. Methods. A total of 60 newly diagnosed MM patients were anal...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Biomed Res Int
Autors principals: Wu, Shenghao, Zheng, Cuiping, Chen, Songyan, Cai, Xiaoping, Shi, Yuejian, Lin, Bijing, Chen, Yuemiao
Format: Artigo
Idioma:Inglês
Publicat: Hindawi Publishing Corporation 2015
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4575715/
https://ncbi.nlm.nih.gov/pubmed/26425561
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2015/927105
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars